NO985908L - FremgangsmÕte til Õ behandle leversykdom og liknende indikasjoner med vasodilaterende midler - Google Patents

FremgangsmÕte til Õ behandle leversykdom og liknende indikasjoner med vasodilaterende midler

Info

Publication number
NO985908L
NO985908L NO985908A NO985908A NO985908L NO 985908 L NO985908 L NO 985908L NO 985908 A NO985908 A NO 985908A NO 985908 A NO985908 A NO 985908A NO 985908 L NO985908 L NO 985908L
Authority
NO
Norway
Prior art keywords
liver
vasodilators
liver disease
treating liver
low dose
Prior art date
Application number
NO985908A
Other languages
English (en)
Other versions
NO985908D0 (no
Inventor
Allan Joseph Mclean
Original Assignee
Pharmacy And Therapeutic Advis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacy And Therapeutic Advis filed Critical Pharmacy And Therapeutic Advis
Publication of NO985908D0 publication Critical patent/NO985908D0/no
Publication of NO985908L publication Critical patent/NO985908L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det er beskrevet en fremgangsmåte for behandling av leversykdom valgt fra gruppen som består av levercirrhose, toksisk og medikamentell leverskade, en leverparenchymatisk lidelse eller hepatitt, hvor metoden inkluderer administrering til et menneske eller dyr med behov derav en terapeutisk aktiv eller en profylaktisk effektiv lav dosemengde av et vasodilaterende middel som selektivt øker tilførselen av oksygenert blod til leveren ved å øke innstrømning gjennom leverarterien. I en side av oppfinnelsen er den effektive lavdosemengden av vasodilaterende middel som administreres redusert med økende alvorlighet av sykdomstilstanden som blir behandlet.
NO985908A 1996-06-20 1998-12-16 FremgangsmÕte til Õ behandle leversykdom og liknende indikasjoner med vasodilaterende midler NO985908L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/667,147 US5854233A (en) 1993-09-08 1996-06-20 Method of treating liver disease and like indications with vasodilating agents
PCT/AU1997/000384 WO1997048396A1 (en) 1996-06-20 1997-06-18 A method of treating liver disease and like indications with vasodilating agents

Publications (2)

Publication Number Publication Date
NO985908D0 NO985908D0 (no) 1998-12-16
NO985908L true NO985908L (no) 1999-02-12

Family

ID=24676993

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985908A NO985908L (no) 1996-06-20 1998-12-16 FremgangsmÕte til Õ behandle leversykdom og liknende indikasjoner med vasodilaterende midler

Country Status (10)

Country Link
US (1) US5854233A (no)
EP (1) EP0964682A4 (no)
JP (1) JP2000513341A (no)
KR (1) KR20000022094A (no)
CN (1) CN1226164A (no)
AU (1) AU735980B2 (no)
CA (1) CA2258696A1 (no)
IL (1) IL121096A0 (no)
NO (1) NO985908L (no)
WO (1) WO1997048396A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
DE19919585A1 (de) * 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
DE10030139A1 (de) * 2000-06-20 2002-01-10 Cmi Ag Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae
JPWO2002028431A1 (ja) * 2000-10-02 2004-02-12 日本ケミファ株式会社 カルシウムチャネル拮抗剤を有効成分として含有する肝疾患治療剤
DE60118592T2 (de) * 2000-10-06 2007-05-16 Phytrix Inc. Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus
PT1326624E (pt) * 2000-10-06 2005-01-31 Phytrix Ag Processo para a preparacao de extractos de phyllanthus
DE10120627A1 (de) * 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
WO2005102353A1 (en) * 2004-04-22 2005-11-03 Howard J Smith & Associates Pty Ltd Supportive treatment of liver disease
US20110274755A1 (en) * 2004-04-22 2011-11-10 Smith Howard J Supportive treatment of liver disease
US9125405B2 (en) * 2008-10-28 2015-09-08 Bausch & Lomb Incorporated Contact lens solution with a tertiary amine oxide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668619A (en) * 1980-10-09 1981-06-09 Yamanouchi Pharmaceut Co Ltd Nifedipine-containing solid composition
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
EP0502143B1 (en) * 1990-09-07 1995-11-08 Universidad De Alicante Composition for treating ocular pain
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
JPH0529528A (ja) * 1991-07-19 1993-02-05 Hitachi Ltd 半導体集積回路装置およびそれに用いるリードフレーム
DE69430807T2 (de) * 1993-09-08 2002-12-19 Pharmacy And Therapeutic Advisory Consultancy Ltd., London Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
AU7647294A (en) * 1993-09-08 1995-03-27 Pharmacy And Therapeutic Advisory Consultancy Ltd. A method of treating liver disease and like indications with vasodilating agents

Also Published As

Publication number Publication date
JP2000513341A (ja) 2000-10-10
WO1997048396A1 (en) 1997-12-24
AU3083397A (en) 1998-01-07
CA2258696A1 (en) 1997-12-24
IL121096A0 (en) 1997-11-20
AU735980B2 (en) 2001-07-19
US5854233A (en) 1998-12-29
EP0964682A4 (en) 2002-11-06
CN1226164A (zh) 1999-08-18
KR20000022094A (ko) 2000-04-25
EP0964682A1 (en) 1999-12-22
NO985908D0 (no) 1998-12-16

Similar Documents

Publication Publication Date Title
Takeshtta et al. Immediate Appearance of Coronary Collaterals during Ergonovine-lnduced Arterial Spasm
BR9813524A (pt) Processos para tratamento de toxicidades associadas com a administração de um agente terapêutico a um mamìfero, para tratamento de toxicidades associadas com a exposição de um mamìfero à terapia de radiação, para tratamento de neuro- ou nefrodistúrbios em um humano, e, para tratamento de distúrbios e sintomas clìnicos associados com diabetes do tipo i ou do tipo ii em um humano
JP2002522485A5 (no)
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
NO985908L (no) FremgangsmÕte til Õ behandle leversykdom og liknende indikasjoner med vasodilaterende midler
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
KR950016760A (ko) 치질 치료제
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
DE69534039D1 (de) Verwendung von valin zur herstellung eines medikaments zur leberregeneration
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
BR0012661A (pt) Métodos de tratamento e métodos de triagem de drogas
NO984974L (no) Middel som forbedrer pulmonar sirkulasjon
DE69326627D1 (de) Therapeutisches Mittel gegen drohenden Abortus
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
MINAMI et al. Extraluminally applied acetylcholine and substance P on the release of EDRF
Jorgensen et al. Lack of effect of transdermal nicotine on 3 cases of primary sclerosing cholangitis
DK200000687A (da) Middel til forsøgelse af afgivelsen af cerebral acetylcholin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application